Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Inclusion Criteria:

1. Patients voluntarily participated in the study, signed the informed consent, and hadgood compliance;
2. Age 18-75 (including 18 and 75), gender is not limited;
3. Histologically and/or cytologically confirmed metastatic colorectal cancer (stage IV);
4. The patient with at least one measurable lesion (RECIST 1.1) achieved partialremission after 8 cycles of first-line standard chemotherapy (FOLFOX combined withbevacizumab), and the disease remained in an unresectable state.
5. ECOG performance status of 0-2 points;
6. Expected survival ≥12 weeks;
7. Blood test (without blood transfusion within 14 days) 1) Neutrophil absolute value ≥1.5×10^9/L, platelet ≥100×10^9/L, hemoglobin ≥90g/L); 2) Liver function test (aspartate aminotransferase and glutamate aminotransferase ≤3×ULN, bilirubin ≤1.5×ULN;In case of liver metastasis, AST and ALT≤5×ULN); 3) Renal function (serum creatinine ≤1.5×ULN, or creatinine clearance (CCr)≥60ml/min);
8. Men and women of childbearing age must use effective contraceptive methods.

Exclusion Criteria:

1. Received major surgery within 4 weeks prior to the first drug administration;radiotherapy, radiofrequency ablation, chemotherapy, immunotherapy or moleculartargeted therapy for tumors within 2 weeks, and other investigational drugs;
2. Previously received anti-vascular small-molecule targeted drug therapy, such asfuquinitinib, regofenib, etc.;
3. A history of severe intolerance to bevacizumab and capecitabine or 5-Fu (i.e., grade 4toxicity of one of these drugs; Class 3-4 toxicity of other co-administered drugs isnot excluded);
4. Known brain or meningeal metastases:
5. Have hypertension that is not well controlled by antihypertensive medications (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);
6. Obvious clinical bleeding symptoms or obvious bleeding tendency and hemoptysis within 3 months prior to treatment. Or treatment of venous/venous thrombosis events withinthe preceding 6 months, such as cerebrovascular accidents (including transientischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis andpulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin, orlong-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day) isrequired;
7. Active heart disease, including myocardial infarction, severe/unstable angina in the 6months prior to treatment. Echocardiography showed that the left ventricular ejectionfraction was less than 50%, indicating poor arrhythmia control.
8. The patient had other malignancies (except cured basal cell carcinoma of the skin andcarcinoma in situ of the cervix) within the previous 5 years or at the same time;
9. Known allergy to the study drug or any of its excipients;
10. Severe active infection or uncontrolled infection;
11. Any other disease, a clinically significant metabolic abnormality, abnormal physicalexamination or abnormal laboratory examination, for which, in the investigator'sjudgment, there is reason to suspect that the patient has a disease or conditionunsuitable for the use of the investigational agent;
12. Urine routine indicated urine protein ≥2+, and 24 hours urine protein quantity >1.0g.